This grant supports research and development of monoclonal antibodies for the prevention and treatment of infections caused by select emerging or re-emerging viruses, strengthening the EU's preparedness and response capacities for infectious disease outbreaks. Expected outcomes include improved scientific access to experimental antibodies, new therapeutic options for epidemic or pandemic settings, and further diversification of prophylactic and therapeutic research capabilities in Europe.
| Agency | HORIZON (EU) |
|---|---|
| Region | EU |
| Country | N/A |
| Legal form | Company, NGO, Government organization, Private person, Other |
| Start date | 10 Feb 2027 |
| End date | 13 Apr 2027 |
| Max funding | 9,000,000–10,000,000 EUR per grant |
| Budget | 37,300,000 EUR |
| Coverage | Not explicitly stated; see Horizon Europe RIA funding rules for typical rates. |